Member Info for Bella6532

Guys they are here to try and disrupt so they can keep a lid on the SP/get some scaredy cat PI to sell a few shares. Someone (II) is loading up and/or selling some of their holding to another II. It's all about working shares to fill orders. Once the deals are done they will disappear as quickly as they appeared.

Including a couple from yesterday...sneaky aren't they?

17-Oct-23 16:20:50 136.50 50,000 Unknown* 68.25k O

17-Oct-23 12:23:55 134.50 50,000 Unknown* 67.25k O

18-Oct-23 17:08:07 138.00 35,500 Unknown* 48.99k O

18-Oct-23 16:55:25 138.486 16,955 Unknown* 23.48k O

18-Oct-23 16:54:52 140.986 20,267 Unknown* 28.57k O

18-Oct-23 16:54:44 138.486 16,955 Unknown* 23.48k O

18-Oct-23 16:54:40 141.486 15,018 Unknown* 21.25k O

18-Oct-23 16:54:39 140.732 928 Unknown* 1,306 O

18-Oct-23 16:54:07 140.985 20,267 Unknown* 28.57k O

18-Oct-23 16:54:05 141.485 15,018 Unknown* 21.25k O

18-Oct-23 16:54:05 140.732 928 Unknown

Go figure:

17/10/2023 4.34M so far

16/10/2023 3.94M

13/10/2023 2.94M

12/10/2023 4.33M

11/10/2023 5.42M

10/10/2023 4.17M

09/10/2023 1.59M

06/10/2023 942.86K

Golfnut59....the markets aren't nervous about funding...they love funding...PI's are the ones that get nervous becuase they often don't get a look in.

Guys...some large trading early this morning...might see some late trades posted again. All this bla bla bla is a distraction...they just want your shares to fill orders. Liquidity at the moment is tight. Funding IS NOT a problem and WILL NOT BE A PROBLEM. Just sit tight, ignore the noise and wait for the data...THAT'S WHAT THE MARKETS WANT...DATA. We are an early stage investment...this is not the LSE...this is still early stage and you have to be patient...very patient. We are only a few weeks away from receiving the first batch of DATA...and potentially only weeks away from signing one or more new Licencing Deals which I believe will include the upfront payments and financing we will need down the road. Right now MONEY IS NOT AN ISSUE...£m's IN THE BANK still.

Fridays UT makes it look like a drop in SP this morning. Fridays close was actually 151.9524. Openings and Closes are often very misleading...

Moneysponge..'Do you think she is in isolation and that nobody else at novartis knows.'

She won't be in isolation at Novartis and she won't be in isolation within the industry either. They all know...but what she has confirmed is what they are all looking for....data, scale, efficacy...

If the 2 weekly trial shows greater efficacy then deals might be struck sooner or at least some MOUs signed...my guess is Avacta know they pretty much have a partnership or AA deal in the bag hence funding 'no need to worry' comments...

Looking for data from higher doses at scale....and efficacy

C7 for sure...but her very last comment is interesting...

Icecool..'Obviously if the patients are still seeing benefits, they can continue on the trial and any extra data is just a bonus.'

What is the protocol? If we call it at C7...do the patients get to continue to receive AVA6000 at that dosage if they are benefitting or do they automatically move to P2. If the later then P2 would have to start quickly to avoid large gap between treatments. Or are they moved over to 2 weekly trial...

Anyone know what might happen..?

Https://www.globenewswire.com/news-release/2023/01/09/2585043/0/en/NovalGen-appoints-Dr-Michael-Owen-and-Mr-Scott-Clark-to-the-Board-of-Directors.html

Still says he's with Avacta.

Https://avacta.com/avacta-announces-new-appointments-to-the-scientific-advisory-board-of-its-therapeutics-division/

And how influential are the 3 new appointments...

Yes Dr.Owens seems to have influence but:

,Avacta Group plc announced that the Dr. Mike Owen has stepped down from his role as Non-executive Director of the Avacta Group plc Board, a position which he has held since 2015, with effect from 24 March 2021..

July 2017 Dr, Mike Owen joined Glythera as Non-Exec.

Jan 2018 Avacta PofC with Glythera

Brighty1...Dr, Mike Owen also joined Glythera as a Non-Exec. Glythera rebranded and is now called Iksuda.

Avacta where working with Glythera on an affimer project...not sure what happened to it all and whether it's still ongoing or dead in the water...

https://iksuda.com/2018/01/positive-outcome-of-proof-of-concept-study-with-glythera-and-follow-on-drug-development-partnership/

It's a big Rugby weekend...

Have a good one guys and gals...

I'm hoping P2 will be based on C7 dose administered 2 weekly to include early and late stage STS....now that really would be awesome...

In person conferences generate lots of discussion. I've sat for hours listerning to the most boring speakers but then had the most interesting and informative conversations with little guy on the fringes. I've picked up all sort of good and bad information eves dropping or chatting to competitors, suppliers, customers etc...

They are great places and as I've said it's not all about the one with the biggest and best stand or on the main stage...

Jive...'and is released as part of a presentation at the January conference.' I don't think so. The data will be released latest year end to get as much pre-conference publicity.

Could be wrong of course...but from what I've seen and heard of Conferences these days nothing has changed since my day way back when apart from Online/Zoom Conferences during Covid but now attendees are very much looking for the in person conferences again because of the networking opportunitities and ear wigging that goes on...

Nah...it's all about networking in the US and it's not about what goes on on stage or Poster Rooms, it's about side meetings, arranging after the event meetings, business card exchanges etc...these Conferences are large and everyone present in whatever room will have sent out invitations to their target audience. Being there is great...not being there is really bad news.

BV...check Slide 'Clinical Regulatory Strategy' on Investor Meet Results Presentation...When 1a 3 week and 1a 2 week studies are complete they will use data from both studies to determing the dose for the next Phase whcih is shown as P2 'Anticipated Pivotal Phase 2 Efficacy Study in STS'. 1b is not shown and a little earlier he does say they don't believe 1b will be needed.

For others on here:

C7 now in progress and due to end before year end and the dose is 385mg/m2 which is equivalent to 3.5 times the normal Dox dose.

C7 is the final Cohort in 3 weekly dosing.

'ALL CLINICIANS INVOLVED IN THE STUDY WOULD USE THE SAME WORD...'REMARKABLE'....

'Almost complete absence of Grade 3 toxicitites.'

'Seeing none of the drug related cardio toxicity.'

'Seen very clear signs of clinical activity in several patients.'

'High levels of dox seen in the tumour tissue.'

Relatively short 2 weekly dosing study will run in parallel to define dosing for Phase 2.

2 weekly dosing group - ' frequent dosing often gives better outcomes'

'doxorubicin is typically dosed every three weeks in order for patients to recover from the side effects of treatment'

So if the side effects are nil or minimal they want to try 2 week dosing to see if they get the same or better tolerability and potentially even better efficacy. Hence running it in parallel.

Now if 2 weekly shows even better efficacy than 3 weekly at the same dosing end point ie C7 if that is the 3 weekly end point if agreed level then they are then hoping to be able to move straight on the P2. I assume then P2 will be a 2 weekly study.

Now, if 2 weekly isn't sucessful and side effects are observed or toxicity builds up in the blood etc then I assume 2 weekly will be stopped and said patients will be moved to 3 weekly after a determined recovery time and 1b might be back in play again.